Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00915577 | Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe | PHASE3 | COMPLETED | 74 | — | — | Aug 1, 2005 | Apr 1, 2006 | Jun 8, 2009 | - | — |
| NCT00912860 | Immunogenicity and Safety Study of Serum-Free Avonex | PHASE2 | COMPLETED | 155 | — | — | Jan 1, 2003 | Jan 1, 2005 | Jun 10, 2009 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1st Injection | EXPERIMENTAL | Manual injection with pre-filled syringe. |
| Single-use autoinjector | EXPERIMENTAL | Single-use autoinjector with Avonex pre-filled syringe |
| 1 | EXPERIMENTAL | serum-free avonex given IM |
| Name | Type | Description |
|---|---|---|
| Interferon beta-1a | DRUG | 30mcg, IM once-a-week |
| Single-use autoinjector | DEVICE | Single-use autoinjector with Avonex 30mcg pre-filled syringe |
Inclusion Criteria: * Must be using liquid AVONEX® to treat MS. In addition, the subject must be on liquid AVONEX® for 12 weeks prior to the Screening Visit. * Must have a BMI of 19 to 28 kg/m², inclusive, and a minimum body weight of 50 kg at Screening. * Must be able to physically demonstrate use...